TIANJIN, China, Oct. 26, 2026 /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") recently hosted the second Sinopec International Catalyst Customer Conference in Tianjin under the theme "Catalyzing Collaboration, Shaping a Smarter Future." The event focused on catalyst innovations that support more efficient refining and chemical production. The conference showcased advances in technology, product development and industrial applications, connecting research with the evolving needs of customers worldwide.

The conference brought together representatives of 69 customers and partners from 24 countries and regions, including the Netherlands, Switzerland, Algeria, Brazil, Azerbaijan and South Korea. It provided a platform for exchanging technical expertise, sharing practical experience and exploring opportunities for cooperation across the refining and chemical industries.

Catalysts play a central role in petroleum refining and chemical manufacturing, helping producers improve energy efficiency, reduce carbon emissions, upgrade processes and develop new materials. As the industry pursues more sustainable production, closer collaboration among technology developers, manufacturers and customers is becoming increasingly important.

Drawing on decades of research and development, Sinopec has developed core technologies across refining and chemical catalysts. Its portfolio includes nearly 300 products across seven categories: refining, polyolefins, basic organic raw chemicals, coal chemicals, environmental protection, adsorbents and additives, and oilfield chemicals. These products support a broad range of industrial processes and applications.

Sinopec has served international catalyst markets for more than 20 years, combining products with technical services for customers in over 40 countries and regions across Asia, Africa, Europe and the Americas. Between 2021 and 2025, the company exported 14 catalyst types for the first time, including catalysts used in propane dehydrogenation, xylene isomerization and continuous catalytic reforming. It also added 13 export destinations, including Canada, the United Kingdom and Argentina.

The company's catalyst business has established trade partnerships with more than 30 countries participating in the Belt and Road Initiative. Its products and technical support help customers upgrade refining processes and improve fuel quality, contributing to the development of local refining and chemical industries.

The customer conference forms part of Sinopec's efforts to strengthen technical exchanges and align catalyst development with industrial needs. The company plans to continue developing efficient catalysts that support more sustainable production, improve its global service network and work with international partners to bring technological advances into wider industrial use.

For more information, visit SINOPEC's official website.

• Launch of HKEX Artificial Intelligence Index and HKEX Semiconductor Index to provide benchmarks for two key technology themes
• HKEX continues to expand proprietary index suite and broaden coverage of emerging technology trends
• License agreement with Southern Asset Management to issue ETFs based on the HKEX Artificial Intelligence Index in Chinese Mainland

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) is pleased to announce the launch of the HKEX Artificial Intelligence Index and the HKEX Semiconductor Index. These new indices further expand HKEX's proprietary index offering and provide investors with new benchmarks to capture opportunities arising from two of the most dynamic technology themes.

HKEX is also pleased to announce that it has entered into a licensing agreement with China Southern Asset Management Company Limited (Southern Asset Management) for the introduction of exchange traded funds (ETFs) based on the HKEX Artificial Intelligence Index in the Chinese Mainland. Details of the product launch will be shared in due course.

Richard Leung, HKEX Group Chief Information Officer, said: "We are delighted to be launching these new thematic indices. Artificial intelligence and semiconductors are transforming industries and becoming increasingly important drivers of growth and innovation globally. At HKEX, we are committed to continuously expanding our index suite to give investors more ways to capture these trends and participate in the growth of the region's technology ecosystem."

Mr Leung added: "We are pleased to be licensing the HKEX Artificial Intelligence Index to Southern Asset Management for ETF products in the Chinese Mainland and look forward to partnering with other market participants to develop more investment products based on our index suite, increasing investor choice and further elevating the depth and vibrancy of our markets."

Yang Xiaosong, Southern Asset Management General Manager, said: "We are honoured to be licensed by HKEX to develop an ETF tracking the HKEX Artificial Intelligence Index in the Chinese Mainland market. This is an important example of Southern Asset Management putting its international strategy into practice and serving investors' needs for diversified asset allocation. Through this collaboration, we will turn the opportunities across Hong Kong's AI value chain into an index-based tool that mainland investors can access conveniently. Looking ahead, we will continue to enrich our product offering for cross-market connectivity, build an investment bridge between the mainland and Hong Kong capital markets, and support two-way empowerment and a virtuous cycle between the technology sector and capital markets in a high-standard opening-up environment."

The HKEX Artificial Intelligence Index is designed to measure the performance of 40 Hong Kong-listed companies with high exposure to the artificial intelligence (AI) value chain. The index provides broad exposure to a five-layer AI stack across the AI ecosystem, spanning the areas including chip design, data centres, AI infrastructure, AI models, as well as software and physical applications. Constituents are selected and weighted using a fundamental-tilted approach, designed to identify companies with meaningful investment in AI research and development and capital expenditure. This offers investors with a representative benchmark for capturing the development of the Hong Kong-listed AI sector.

Meanwhile, the HKEX Semiconductor Index measures the performance of the 30 largest semiconductor-related companies listed in Hong Kong. The index captures exposure across multiple segments of the semiconductor industry, including semiconductor manufacturing, equipment, electronic components, computing hardware and storage, providing investors with a benchmark to track developments across the Hong Kong-listed semiconductor value chain. 

The launch of the two indices further strengthens HKEX's proprietary index offering and broadens its coverage of emerging technology themes, supporting the development of new index-linked investment products and providing investors with more ways to capture opportunities in Hong Kong's markets.

More information on the HKEX Artificial Intelligence Index and the HKEX Semiconductor Index, including their index methodologies, is available on the HKEX website.

About HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is a publicly-traded company (HKEX Stock Code: 388) and one of the world's leading global exchange groups, offering a range of equity, derivative, commodity, fixed income and other financial markets, products and services, including the London Metal Exchange.

As a superconnector and gateway between East and West, HKEX facilitates the two-way flow of capital, ideas and dialogue between China and the rest of the world, through its pioneering Connect schemes, increasingly diversified product ecosystem and its deep, liquid and international markets.

HKEX is a purpose-led organisation which, across its business and through the work of HKEX Foundation, seeks to connect, promote and progress its markets and the communities it supports for the prosperity of all.

www.hkexgroup.com 

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Recently, Newborn Town's game-oriented social platform TopTop has launched "Slap Showdown", an AI-powered 3D interactive mini-game developed in collaboration with Viggle, a company specializing in physics-native world models. The launch brings world model technology into social gaming, offering users a more personalized and engaging interactive experience.

Developed by TopTop and powered by Viggle's self-developed Joint Space-Time (JST) world model, "Slap Showdown" lets users turn uploaded photos into customized 3D characters and take them straight into the game.

Launched in September, "Slap Showdown" has gained particular traction in Japan, among Spanish-speaking users in North America, and across the Middle East. It is now available in multiple countries and regions worldwide.

From Better Gameplay to a Richer Ecosystem: How World Models Could Redefine Social Gaming on TopTop

In terms of gameplay, "Slap Showdown" combines AI-generated 3D characters with multiplayer interaction. Players can simply upload a photo from their phone and generate a personalized 3D character in around 30 seconds, whether it's an anime protagonist, a cyberpunk cyborg, or a LEGO minifigure. They can then bring their custom characters into the game and face off against other players in fun, interactive battles.

As players use controls such as press-and-hold, tap, and drag, the 3D characters respond with realistic, physics-based movements. This takes AI-generated characters beyond visual customization, integrating them directly into the gameplay experience.

According to TopTop's operations team, "Slap Showdown" has attracted a growing base of highly engaged, high-spending-potential players in its first month since launch. The game has recorded a 97% match completion rate, while its game-start rate has also exceeded the platform-wide average.

The depth of user engagement is further illustrated by individual player activity. One player in Japan completed 1,041 matches over 22 days, reaching a daily peak of 151 matches and averaging one match every 9.5 minutes. Another particularly avid player in Eastern Europe completed 735 matches in just 11 days, averaging 66.8 matches per day and peaking at 126 matches in a single day.

For a UGC-driven social gaming platform such as TopTop, mini-games serve as entry points and traffic drivers, while social features underpin retention and monetization. Personalized 3D avatars add another dimension to that experience. Beyond their visual appeal, they give users new ways to express themselves, interact with friends and share memorable moments. In turn, richer gameplay and more meaningful social interactions can help improve retention, attract new users and strengthen engagement across the platform.

"Slap Showdown" marks a successful step in TopTop's efforts to deepen its application of AI technology, as well as a starting point for using world models to enhance gaming and social experiences. TopTop's operations team said future game releases could make greater use of AI-powered 3D generation, extending beyond avatars to include customized environments. Existing games could also be revitalized by the introduction of new gameplay features, potentially driving stronger retention and user acquisition.

Beyond enriching gameplay, world model capabilities could also reshape social interaction itself, enabling more immersive, face-to-face experiences in virtual spaces. "We're constantly exploring how AI can transform gaming and social interaction, while bringing new energy and capabilities to our UGC ecosystem," TopTop's operations team said.

Viggle Unveils Physics-Native Model JST-2, Setting Its Sights on Becoming the Infrastructure Layer for Physical AI

The world model technology powering "Slap Showdown" is provided by Viggle.

Founded in 2022, Viggle has focused on developing physics-native world foundation models. Its self-developed JST model can generate 3D characters, motion and environments directly, providing a foundation for gaming and a growing range of AI applications.

Viggle previously attracted widespread attention with Meme Maker, its AI-powered video creation product. The tool enables users to animate static characters and generate videos by applying specified movements, making AI character animation and video creation more accessible. In August 2024, Viggle raised USD 19 million in a Series A funding round led by Silicon Valley venture capital firm Andreessen Horowitz (a16z).

However, video creation was an early application of this technology. Viggle's longer-term ambition is to make JST a foundational technology for AI-powered experiences across gaming, social platforms and other applications.

Viggle is now further expanding its technological boundaries. On 19 October, Viggle launched JST-2 in full, likening its significance for world models to GPT-2's role in the evolution of language models.

Unlike many world models that infer physical structure indirectly from pixels, JST-2 is built around a physics-native architecture designed to learn the structure and dynamics of the 3D world directly. Its underlying representation consists of units resembling digital "atoms." Each has a defined position in three-dimensional space, along with physical properties such as material, color and mass, and information describing how it moves and responds to forces. This allows the model to do more than generate convincing images. It can represent and generate 3D characters, motion and scenes with an underlying understanding of their physical properties.

To support this approach, Viggle has developed an integrated technology stack spanning tokenization, model architecture, data engine, pre-training and post-training. After four years of research and development, JST-2 can generate characters, motion and scenes within a single unified architecture.

Compared with other approaches, JST-2 also demonstrates cost efficiency. JST-2 can generate a 3D scene in seconds, at an inference cost of less than one US cent. Once created, the content can be rendered locally without repeatedly running the foundation model to generate each frame.

It is noteworthy that world model technology remains at an early stage, but Viggle is already working toward more advanced capabilities.

Its next-generation model, JST-3, is intended to become a comprehensive world simulator. Such a system could underpin future game and graphics engines, while also serving as a virtual training environment for robotics and other forms of physical AI.

The longer-term goal is for JST-3 to learn the physical rules governing its simulated world directly from data, rather than relying on rules explicitly written by developers.

For Newborn Town, its investment in and partnership with Viggle represents an important step in exploring how advanced AI can reshape social gaming, promoting a deep integration of AI technology with its business operations.

As a leading global social entertainment company, Newborn Town has continued to deepen the use of AI across key areas in recent years, including product R&D, social recommendation systems, intelligent operations, safety and risk management, and marketing and user acquisition, supporting ongoing business growth.

Meanwhile, the company also continued to invest across the AI ecosystem, backing projects in areas including world models, AI companionship, AI Agents and AI interactive gaming. These investments have further enriched its AI application ecosystem, with Viggle among the AI companies previously backed by Newborn Town.

"Slap Showdown" represents an early step in bringing world models into social gaming. For Newborn Town and Viggle, the next challenge is to turn increasingly sophisticated AI capabilities into experiences that users find genuinely engaging — and compelling enough to keep coming back.

SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the preliminary positive research results of the investigator-initiated trial (CT041-CG4010, NCT06857786) in China of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product against Claudin18.2), as consolidation therapy following adjuvant treatment for locally advanced gastric or gastroesophageal junction cancer, have been presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Poster number: 1056P)^[1].

Prognosis remains suboptimal in high-risk patients with locally advanced gastric cancer who have undergone curative gastrectomy, with a 1-year disease-free survival (DFS) rate of only about 73–78%, while the 2-year DFS rate further declines to 58–64%^[2], underscoring the urgent need for novel therapeutic strategies. The CT041-CG4010 trial represents an important attempt worldwide to explore CAR T-cell therapy for post-surgical adjuvant treatment of gastric cancer. This trial enrolled locally advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJC) patients who had undergone radical gastrectomy with D2 lymphadenectomy, with pathologically confirmed (y)pT4aN+ or T4bNany disease. The primary endpoint was safety, and secondary endpoints included efficacy and pharmacokinetics.

According to the study results, up to the data cut-off date (September 14, 2026), 10 patients received satri-cel infusion. All patients had pathological stage T4a or T4b with node-positive disease, of whom up to 80% had N2/N3 stage (60% N3). Lauren diffuse type accounted for 90% of patients and signet-ring cell carcinoma for 70%, collectively indicating a patient population at extremely high risk of postoperative recurrence.

Seven patients had completed at least 12 months of postoperative follow-up, of whom five patients completed M18 post-surgery follow-up, including 2 patients who completed M21 follow-up. None of the infused patients experienced postoperative recurrence or metastasis of gastric cancer; the 12-month (M12) DFS rate was 100% and the median DFS was not reached. One patient was minimal residual disease (MRD)-positive by circulating tumor DNA (ctDNA) before infusion, which turned negative at the first assessment after satri-cel infusion, and remained negative during subsequent follow-up. In terms of pharmacokinetics, all patients showed solid CAR T expansion.

As for safety, the incidence of cytokine release syndrome (CRS) was 80%, and all events were grade 1–2, with a median time to recovery of 4 days. No immune effector cell-associated neurotoxicity syndrome (ICANS) occurred, and no adverse events leading to death were reported. The overall safety profile was manageable.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, stated, "We are pleased to see that satri-cel has shown encouraging preliminary results in the novel exploratory setting of adjuvant therapy following gastrectomy. For patients with locally advanced gastric cancer at high risk of postoperative recurrence, the benefit of existing adjuvant therapies remains limited. In this study, none of the patients have experienced recurrence to date, the 12-month DFS rate reached 100%, and one patient's MRD converted from positive to negative. These findings suggest that satri-cel may clear minimal residual disease and potentially alter the disease course for these patients, with a more favorable safety profile than in the later-line setting and overall manageable. Building on the approval of satri-cel for later-line treatment of advanced gastric cancer, we will continue to advance its exploration into earlier-line settings such as post-surgical adjuvant therapy and sequential therapy following first-line treatment, with the goal of providing better curative opportunities for a broader patient population."

About Satri-cel
Satri-cel is an autologous CAR T-cell therapy product against the protein Claudin18.2 that is the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors. It was approved by the NMPA in June 2026 for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy, making it the world's first approved CAR T-cell therapy product for solid tumors.

The Company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China (NCT05911217), an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786) and an IIT for sequential therapy following first-line treatment for G/GEJA (NCT07179484).

About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

References

• The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings.

SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced multiple clinical data updates for IBI363 (Takeda R&D code: TAK-928), at the 2026 European Society for Medical Oncology (ESMO) Congress. IBI363/TAK-928 is a potential first-in-class PD-1/alpha-biased IL-2 bispecific fusion protein being jointly developed by Innovent and Takeda globally.

Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent, said: "The latest IBI363/TAK-928 data presented at 2026 ESMO across lung and gastric cancer studies further demonstrate its broad antitumor potential. Encouraging efficacy signals were observed in both first-line and later-line/immunotherapy-resistant cancers. Together with Takeda, we will continue to advance the global development of IBI363/TAK-928 and seek to provide new treatment options for more patients."

First-Line NSCLC: IBI363/TAK-928 Continues to Show Encouraging Efficacy Trend

Title: IBI363 (TAK-928) plus chemotherapy as first line (1L) treatment for advanced non-small cell lung cancer (NSCLC): Update of a phase 1b study

Abstract number: 1044P

• This study represents the first stage of a proof-of-concept (PoC) clinical study evaluating IBI363/TAK-928 in combination with platinum-based doublet chemotherapy (PDC) in patients with previously untreated locally advanced or metastatic NSCLC. The study is designed to evaluate the safety and efficacy of IBI363 plus chemotherapy in the first-line treatment of NSCLC and to explore dose-optimization strategies. Initial data from the study were first presented at the 2026 ASCO Annual Meeting [link]. Updated results with a longer follow-up period were presented at the 2026 ESMO Annual Meeting.
• As of April 7, 2026, a total of 80 patients had been enrolled, including 11 patients in the safety run-in phase and 69 patients in the dose-optimization phase. The median follow-up was 8.9 months, with a range of 0.6 to 12.3 months. Patients enrolled in the dose-optimization phase had PD-L1 tumor proportion scores (TPS) of less than 50%, including patients with TPS of 1–49% and TPS of less than 1%. They were randomized in a 1:1:1 ratio to three dose groups, with generally balanced baseline characteristics across the groups. As of the data cutoff date, 48.8% of patients remained on IBI363 treatment.

IBI363/TAK-928 Continued to Demonstrate Encouraging Efficacy Signals

• IBI363/TAK-928 continued to demonstrate encouraging antitumor activity. In the first-line treatment of patients with PD-L1-negative or PD-L1-low NSCLC, the confirmed objective response rates (cORRs) in the IBI363 1.5 mg/kg, 3 mg/kg and 3→1.5 mg/kg dose groups were 47.4%, 61.9% and 86.4%, respectively. The corresponding disease control rates (DCRs) were 94.7%, 100.0% and 100.0%.
• Overall progression-free survival (PFS) data remained immature.

Manageable Safety Profile with No New Safety Signals with Longer Follow-up

• The overall safety profile of IBI363/TAK-928 in combination with chemotherapy remained manageable across dose groups. With longer follow-up, the safety profile remained generally consistent, and no new safety signals were identified.
• The most frequently reported TEAEs were hematologic — anemia (82.5%), neutrophil count decreased (76.3%), WBC count decreased (66.3%), and platelet count decreased (46.3%) — consistent with the known toxicity profile of the individual agents.

Conclusions and Next Steps

• IBI363/TAK-928 in combination with platinum-based doublet chemotherapy continued to demonstrate encouraging clinical activity in patients with PD-L1 TPS <50% NSCLC in the first-line setting, further supporting its potent antitumor activity as a potential first-in-class PD-1/alpha-biased IL-2 bispecific fusion protein. The second stage of this PoC study, a randomized controlled study evaluating IBI363/TAK-928 plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment for advanced NSCLC, is currently ongoing.

Professor Haiyan Tu of Guangdong Provincial People's Hospital said:

"Following the initial efficacy and safety data presented at the 2026 ASCO Annual Meeting, longer-term follow-up presented at ESMO continued to demonstrate encouraging antitumor immune response with IBI363 in combination with chemotherapy in patients with PD-L1-negative or PD-L1-low advanced NSCLC in the first-line setting, with the potential for durable clinical benefit. As the randomized controlled phase of the study progresses, we look forward to further evaluating its clinical potential as a new treatment option for these patients."

First-Line G/GEJA: IBI363/TAK-928 Demonstrated Encouraging Efficacy Observed Across PD-L1 CPS Subgroups

Title: IBI363 (TAK-928) plus XELOX as the first line (1L) treatment for advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA)

Abstract number: 1008RO

• This is the investigator-initiated Phase 1b clinical study evaluating IBI363/TAK-928 in combination with capecitabine and oxaliplatin (XELOX) as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA; NCT06610799).
• As of July 9, 2026, a total of 46 patients had been enrolled, including seven patients in the dose-escalation phase and 39 patients in the dose-expansion phase. The median follow-up duration was 9.2 months, with a range of 7.9 to 10.8 months. Distant metastases were present in 97.8% of patients, including liver metastases in 45.7% and peritoneal metastases in 28.3%. 34.8% of patients have PD-L1 CPS<5 and 60.9% of patients have PD-L1 CPS≥5.

IBI363/TAK-928 Demonstrated Encouraging Response Signals in 1L G/GEJA Regardless of PD-L1 CPS Level

• Among patients who had undergone at least one post-baseline tumor assessment, the cORR was 78.6% and the DCR was 100.0% in the overall population (n=42). In the dose-expansion cohort receiving IBI363 at 1.5 mg/kg (n=35), the cORR was 80.0% and the DCR was 100.0%; and the cORRs were 90.0% and 76.9% in patients with PD-L1 CPS ≥5 and CPS <5, respectively.

12-Month PFS and OS Remained Immature, with Potential Signals of Survival Benefit

• In the overall population (n=42), the 12-month PFS and overall survival (OS) rates were 52.8% and 84.5%, respectively. In the dose-expansion cohort receiving IBI363 at 1.5 mg/kg (n=35), the 12-month PFS and OS rates were 55.2% and 84.5%, respectively. Follow-up is ongoing.

Manageable Safety Profile with No New Safety Signals

• The incidence of Grade 3 or higher treatment-emergent adverse events (≥Grade 3 TEAEs) was 45.7% in the overall population and 46.2% in the dose-expansion cohort. No treatment-related deaths were reported.
• The most common TEAEs were anemia (69.6%; ≥Grade 3, 13.0%), decreased platelet count (60.9%; ≥Grade 3, 8.7%) and decreased neutrophil count (43.5%; ≥Grade 3, 13.0%). Most events were mild to moderate and manageable with standard clinical management.
• The safety profile was generally consistent with the known safety profile of the individual agents.

Conclusions and Next Steps

• The first Phase 1b clinical study of IBI363/TAK-928 in first-line HER2-negative G/GEJA demonstrated encouraging efficacy and safety signals. Potential clinical benefit was observed in patients across different PD-L1 CPS expression levels, consistent with the differentiated mechanism of action of IBI363 and findings from previous clinical studies.
• A randomized controlled PoC study is planned to initiate to further evaluate the potential of IBI363 plus chemotherapy in the first-line treatment of G/GEJA.

Professor Pengfei Yu of Zhejiang Cancer Hospital said:

"Since the establishment of PD-1 antibody plus chemotherapy as the standard first-line treatment for HER2-negative G/GEJA, improvements in efficacy have gradually reached a plateau. In this study, IBI363 plus chemotherapy demonstrated encouraging efficacy and a manageable safety profile, with positive signals observed across different PD-L1 CPS expression levels. These findings provide a new opportunity to address the current treatment challenges. We look forward to further exploring IBI363 in the first-line treatment of advanced HER2-negative G/GEJA to potentially provide patients with more comprehensive and effective treatment options."

Immunotherapy-Resistant Lung Adenocarcinoma: IBI363/TAK-928 Significantly Reduced the Risk of Disease Progression

Title: IBI363 (TAK-928) plus bevacizumab (Bev) vs docetaxel (DTX) in patients with locally advanced or metastatic immunotherapy (IO)-resistant lung adenocarcinoma without actionable genomic alterations: a randomized phase Ib study

Abstract number: 1952RO

• Previous studies have demonstrated a favorable long-term safety profile and promising survival data with IBI363/TAK-928 monotherapy in patients with immunotherapy-resistant NSCLC [link]. A global Phase 3 study MarsLight-11 is currently underway to further evaluate IBI363 monotherapy in this patient population(NCT07217301).
• This study is the first randomized controlled Phase 1b study of IBI363/TAK-928 in immunotherapy-resistant NSCLC (NCT06468098). It evaluated IBI363/TAK-928 plus bevacizumab versus docetaxel in patients with locally advanced, unresectable or metastatic lung adenocarcinoma without actionable genomic alterations whose disease had progressed following prior immunotherapy. Baseline characteristics were generally balanced between the two treatment groups. Notably, the docetaxel group had higher proportions of patients with a history of smoking and patients with PD-L1 expression of ≥1%.

IBI363/TAK-928 Demonstrated Efficacy Benefit Compared with Standard of Care Therapy

• As of July 6, 2026, the median follow-up time was 8.48 months in the IBI363/TAK-928 treatment group, with a range of 2.1 to 15.1 months, and 7.59 months in the docetaxel group, with a range of 0.2 to 14.8 months.
• The cORR was 20.0% in the IBI363/TAK-928 treatment group, compared with 7.1% in the docetaxel group. Median PFS was significantly prolonged with IBI363/TAK-928, with a hazard ratio of 0.40 (p=0.0006), corresponding to a 60% reduction in the risk of disease progression or death. In the subgroup analysis, the IBI363/TAK-928 treatment group demonstrated a PFS benefit regardless of PD-L1 expression level. OS data remained immature, and follow-up is ongoing.

Manageable Safety Profile with No New Safety Signals

• The incidence of ≥Grade 3 TEAEs was 62.2% in the IBI363/TAK-928 treatment group and 78.0% in the docetaxel group. The most common TEAEs in the IBI363/TAK-928 treatment group were arthralgia (53.3%; ≥Grade 3, 4.4%), anemia (48.9%; ≥Grade 3, 2.2%) and rash (46.7%; ≥Grade 3, 11.1%). Most events were mild to moderate and manageable with standard clinical management.
• No treatment-related deaths occurred in the IBI363/TAK-928 treatment group. One treatment-related death occurred in the docetaxel group.

Professor Jianya Zhou of The First Affiliated Hospital of Zhejiang University School of Medicine said:

"Immunotherapy resistance remains a major challenge in NSCLC, and treatment options after immunotherapy failure remain limited. The results from this first randomized controlled study of IBI363/TAK-928 are highly encouraging. Compared with docetaxel, IBI363/TAK-928 plus bevacizumab significantly reduced the risk of disease progression, with benefits observed regardless of PD-L1 expression level. These findings, consistent with the long-term follow-up data presented at this year's ASCO Annual Meeting, further support the differentiated clinical profile of IBI363/TAK-928 and its evaluation in immunotherapy-resistant nonsquamous NSCLC in the global multicenter Phase 3 MarsLight-11 study. We look forward to IBI363/TAK-928 potentially offering a new treatment option for these patients."

About IBI363/TAK-928 (PD-1/alpha-biased IL-2 Bispecific Fusion Protein)

IBI363/TAK-928 is a potential first-in-class PD-1/alpha-biased IL-2 bispecific fusion protein being co-developed by Innovent and Takeda. It functions by both blocking the PD-1/PD-L1 pathway and selectively activating the IL-2 pathway. The IL-2 arm of IBI363/TAK-928 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, with the aim of minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2 to the tumor.

IBI363/TAK-928 is being evaluated in a series of clinical trials globally, including

• a pivotal Phase II study in China in previously untreated acral and mucosal melanoma
• a global multi-center Phase III trial in immunotherapy-resistant squamous and non-squamous NSCLC
• a pivotal Phase III study in China in advanced CRC refractory or intolerant to standard therapy.
• In parallel, multiple Phase Ib/II trials are evaluating IBI363/TAK-928 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types.

IBI363/TAK-928 has received two Fast Track Designations (FTD) from the U.S. FDA and three Breakthrough Therapy Designations (BTD) from China NMPA so far.

In October 2025, Innovent entered into a license and collaboration agreement with Takeda, under which Innovent and Takeda will co-develop IBI363 (Takeda R&D code: TAK-928) globally and co-commercialize IBI363/TAK-928 in the U.S., and Takeda will exclusively commercialize IBI363/TAK-928 worldwide other than the U.S. and greater China. Takeda will lead global co-development efforts under joint governance and aligned development plan, sharing development costs (60/40 - Takeda/Innovent).

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage.

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high quality outbound internationalization of China's innovative drug industry.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s).

(2) Ramucirumab Injection (Cyramza®), Selpercatinib Capsules (Retsevmo®), Pirtobrutinib Tablets (Jaypirca®) and abemaciclib (Verzenios®) are products discovered and developed by Eli Lilly.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

A Heng Ren Partners survey this month finds at least 99.3% support on five key shareholder issues to boost shareholder value; shareholders want DiDi's board and management to respond with concrete action

BOSTON, Oct. 26, 2026 /PRNewswire/ -- Heng Ren Partners LLC, an active asset manager whose fund owns shares of "the Uber of China," DiDi Global Inc. (OTC Pink: DIDIY), today released the results of a survey of DiDi shareholders showing near-unanimous support for relisting the company's depressed shares on the Hong Kong Stock Exchange.

In 2022 DiDi's shares were delisted from the New York Stock Exchange (NYSE) and moved to trade only OTC (over-the-counter) in the U.S. Despite delivering the most rides in the world, DiDi shares languish because its OTC status disqualifies it from indexes, and most institutional investors avoid buying OTC stocks, which are mostly penny stocks or shell companies. Heng Ren believes a relisting in Hong Kong is the best opportunity for realizing shareholder value and is campaigning for the change in trading venue.

DiDi shares are trading at close to $3.00 down 79% versus the 2021 IPO price of $14.00 per American Depositary Share (ADS). DiDi shares are down approximately 52% in the past year. Aside from the OTC discount, DiDi's lack of communication with shareholders – no shareholder meetings, no public earnings calls – and lack of full board representation, all heighten the perceived risk of investment in DiDi.

Shareholders answered each of the survey's five questions, and at least 99.3% of respondents answered that they want change:

Key findings:

• Hong Kong relisting: 144 respondents to this question (99.3%) want DiDi's shares listed on the Hong Kong Stock Exchange instead of trading OTC in the U.S.
• Shareholders' meeting: All 147 respondents (100%) want DiDi's board to call a shareholders' meeting to discuss the relisting plan.
• Relisting plan: All 145 respondents (100%) want DiDi to disclose its plan for relisting the shares in Hong Kong.
• Earnings calls: 146 respondents (99.3%) want DiDi to open its quarterly earnings calls to all shareholders.
• Independent director: 146 respondents (99.3%) want an election in which shareholders can nominate and choose an independent director to fill a vacant board seat and represent them.

DiDi's shares have traded over-the-counter in the U.S. since the company's June 2022 delisting from the New York Stock Exchange. In December 2021, DiDi announced that it would start preparations for a listing in Hong Kong. To Heng Ren's knowledge, DiDi has not publicly announced a plan or timetable since, and it has not held a shareholders' meeting since 2022.

"DiDi's shareholders have spoken in their answers to this survey, and their message is clear and consistent," said Peter Halesworth, founder, Managing Partner and Chief Investment Officer of Heng Ren Partners in Boston. "Relist, re-engage, and understand we want representation. These are modest requests that any global public company should be able to meet: tell us the plan to relist in Hong Kong, meet with us, open your earnings calls to everyone, and let us elect an independent director.

"We believe relisting in Hong Kong is the most rational outcome for all shareholders, and we think it is consistent with the direction Beijing has encouraged. We call on DiDi's board and management to respond positively with concrete action," Halesworth said.

Taken together, shareholders are making four requests of DiDi's board and management: tell shareholders the plan and timetable for relisting in Hong Kong; hold a shareholders' meeting to discuss shareholder issues; open quarterly earnings calls to all shareholders and interested investors; and let shareholders nominate and elect an independent director.

Heng Ren and shareholders have written letters to DiDi's board and management, and also contacted DiDi's largest shareholders asking them to support relisting in Hong Kong, including SoftBank Group Corp. (TSE: 9984) which owns approximately 21.5% of DiDi's shares, Uber Technologies, Inc. (NYSE: UBER), a 12.8% shareholder, and Tencent Holdings Ltd. (HKEx: 0700), a 7.1% shareholder of DiDi.

"None of this will happen unless all shareholders ask for it," Halesworth said.

Heng Ren Partners LLC invites DiDi shareholders to stay up-to-date and engage in its initiative to see DiDi's shares listed on the Hong Kong Stock Exchange. Visit https://www.hengreninvestment.com/ and click "Bring DiDi Home" for details about the campaign.

About the survey: The survey asked five Yes-or-No questions and was conducted from October 16 to 21, 2026. Participation was voluntary, and the results reflect the views of the hundreds of shareholders surveyed. It is not a scientific sample of all DiDi shareholders.

About Heng Ren Partners

Heng Ren Partners LLC is an SEC-registered investment adviser based in Boston. It manages Heng Ren Investments LP, established in 2013, and Heng Ren Silk Road Investments LLC, a fund launched in 2018. For more information, visit www.hengreninvestment.com.

Media Contact:

Peter Halesworth
Founder & CIO
Heng Ren Partners LLC
info@hengreninvestment.com

Related Links
https://www.hengreninvestment.com

• 中位 OS 較含鉑雙藥化療延長 8.5 個月(25.9 vs 17.4 個月)，死亡風險降低 31%(HR 0.69；95% CI 0.54–0.89；單側 P = 0.0021)。
• 兩年 OS 率為 54.1% vs 37.2%，提高 16.9 %；中位隨訪 32.3 個月，生存獲益持續。
• 校正後中位 OS 相差 9.3 個月(25.9 vs 16.6 個月)：采用預設的 RPSFT 模型進行後續 ADC 治療校正後，死亡風險降低 43%(HR 0.57；95% CI 0.42–0.75)。

成都2026年10月25日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)宣布，在西班牙馬德裡舉行的2026年歐洲腫瘤內科學會(ESMO)大會上，中山大學腫瘤防治中心方文峰教授以口頭報告形式公布了蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊^®)III 期 OptiTROP-Lung04 研究預設的總生存期(OS)最終分析結果(LBA67；優選口頭報告(Proffered paper)|轉移性NSCLC)。結果顯示，在經表皮生長因子受體-酪氨酸激酶抑制劑(EGFR-TKI) 治療後進展的 EGFR 突變局部晚期或轉移性非鱗狀非小細胞肺癌(NSCLC)患者中，蘆康沙妥珠單抗(sac-TMT) 單藥較含鉑雙藥化療顯示持續的 OS 獲益。

該研究的最終無進展生存期(PFS)分析和期中 OS 分析結果已於 2025 年在《新英格蘭醫學雜志》(NEJM)在線發表。經盲態獨立中心審評(BICR)評估的最終 PFS 分析顯示，疾病進展或死亡風險降低 51%(HR 0.49；95% CI 0.39–0.62)。基於此，蘆康沙妥珠單抗(sac-TMT)已於 2025 年 9 月獲中國國家藥品監督管理局(NMPA)批准，用於治療經 EGFR-TKI 治療後進展的 EGFR 基因突變陽性的局部晚期或轉移性非鱗狀NSCLC成人患者。

本次OS最終分析結果表明，中位隨訪32.3個月時，蘆康沙妥珠單抗(sac-TMT) 較含鉑雙藥化療顯示出持續且具有臨床意義的OS改善。此外，含鉑雙藥化療組有 22.6% 的患者接受了後續抗體偶聯藥物(ADC)治療，預設的等級結構保留失效時間(RPSFT)模型校正分析為 OS 主分析提供了補充支持。

安全性方面，延長隨訪後未發現新的安全性信號。蘆康沙妥珠單抗(sac-TMT)組常見治療相關不良事件主要為血液學不良事件和口腔黏膜炎。口腔黏膜炎以 1–2 級為主且可管理，3 級事件發生率為 4.8%。間質性肺病/肺炎在蘆康沙妥珠單抗(sac-TMT) 組僅報告 1 例(0.5%)，在含鉑雙藥化療組報告 2 例(1.1%)，均為 1–2 級。

中山大學腫瘤防治中心方文峰教授表示：「對於 EGFR-TKI 治療後進展的患者，治療的重要目標是延長生存。本次最終 OS 分析進一步明確了蘆康沙妥珠單抗(sac-TMT)單藥相較於含鉑雙藥化療可顯著延長患者OS，降低31%的死亡風險，為這一人群的治療選擇提供了更成熟的長期隨訪證據。」

OptiTROP-Lung04 研究

OptiTROP-Lung04 是一項隨機、多中心、開放標簽 III 期研究，共納入 376 例患者，按 1:1 比例隨機接受蘆康沙妥珠單抗(sac-TMT)單藥治療(5 mg/kg Q2W)或含鉑雙藥化療(培美曲塞聯合鉑類)。主要終點為 BICR 評估的 PFS，OS 為關鍵次要終點。截至數據截止日期(2026 年 8 月 6 日)，中位隨訪時間為 32.3 個月。

關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊^®)

作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型靶向人滋養細胞表面抗原2(TROP2)的ADC，針對NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤及泌尿生殖系統腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)采用獨特雙功能連接子開發而成。該連接子一方面通過與抗TROP2單克隆抗體沙妥珠單抗形成不可逆結合，另一方面在溶酶體中可從貝洛替康衍生物拓撲異構酶I抑制劑有效載荷(KL610023)pH敏感裂解，從而最大限度將有效載荷遞送至腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞並於細胞內釋放有效載荷KL610023。KL610023可誘導腫瘤細胞DNA損傷，進而導致細胞周期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。

於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、制造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。

截至目前，蘆康沙妥珠單抗(sac-TMT)的4項適應症已於中國獲批上市，分別用於：1)既往至少接受過2種系統治療(其中至少1種治療針對晚期或轉移性階段)的不可切除的局部晚期或轉移性三陰性乳腺癌(TNBC)；2)經EGFR-TKI和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰性(HER2-) (免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-) BC；其中前2項適應症已經被納入醫保范圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲NMPA授予6項突破性療法認定。

蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。蘆康沙妥珠單抗(sac-TMT)的兩項新增適應症上市申請已獲NMPA受理，分別用於：1)聯合帕博利珠單抗一線治療程序性細胞死亡配體1(PD-L1)腫瘤比例分數(TPS)≥1%的EGFR基因突變陰性和間變性淋巴瘤激酶(ALK)陰性的局部晚期或轉移性NSCLC；2)PD-L1綜合陽性評分(CPS)<10或早期階段接受過PD-1/PD-L1抑制劑的復發或轉移性TNBC的一線治療，以上兩項申請均被納入優先審評審批程序。目前，公司已在中國開展9項注冊性臨床研究。默沙東已啟動18項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點布局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平台，致力於成為在創新藥物領域國際領先的企業。公司目前擁有 30 余個重點創新藥項目，其中 4 個項目 8 個適應症已獲批上市，2 個項目 3 個適應症處於 NDA 階段，10 余個項目正處於臨床階段。公司成功構建了享譽國際的專有 ADC 及新型偶聯藥物平台 OptiDC™，已有 2 個 ADC 項目 5 個適應症獲批上市，多個 ADC 或新型偶聯藥物產品處於臨床或臨床前研究階段。更多信息請訪問官網 https://kelun-biotech.com/。

• PFS顯著延長：經BICR評估，疾病進展或死亡風險降低51% (HR 0.49；95% CI 0.36-0.65；P<0.0001)，兩組中位PFS分別為15.0個月(95% CI 9.9-NE)和5.7個月(95% CI 5.5-7.4)。
• 緩解更持久：兩組中位緩解持續時間分別為13.6個月和6.8個月(HR 0.47；95% CI 0.29-0.77)。
• OS呈改善趨勢：在本次PFS期中分析時，OS HR為0.58(95% CI 0.38-0.88)，兩組中位OS均未達到。

成都2026年10月25日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)宣佈，在西班牙馬德里舉行的2026年歐洲腫瘤內科學會(ESMO)大會上，同濟大學附屬東方醫院周彩存教授以口頭報告形式公佈了蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊^®)III期OptiTROP-Lung06研究結果(LBA66；優選口頭報告(Proffered paper)|轉移性NSCLC)。

OptiTROP-Lung06研究成果亦同步發表於國際頂級醫學期刊《新英格蘭醫學雜誌》(The New England Journal of Medicine，影響因子=84.5)。

期中分析顯示，蘆康沙妥珠單抗(sac-TMT)聯合默沙東^[1]的抗程序性細胞死亡蛋白1(PD-1)單抗帕博利珠單抗(可瑞達^®[2])較含鉑雙藥化療聯合帕博利珠單抗相比顯著改善了程序性細胞死亡配體1(PD-L1)腫瘤比例分數(TPS)＜1%的表皮生長因子受體(EGFR)基因突變陰性和間變性淋巴瘤激酶(ALK)陰性的晚期非鱗狀非小細胞肺癌(NSCLC)患者一線治療的無進展生存期(PFS)，總生存期(OS)方面亦觀察到獲益趨勢。

經BICR評估，兩組客觀緩解率分別為50.2%和47.3%；深度緩解率分別為28.8%和17.3%。深度緩解定義為達到完全或部分緩解，且靶病灶直徑總和較基線縮小至少50%。

安全性方面，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗的安全性特徵與各單藥已知的安全性特徵總體一致，未觀察到新的安全性信號。與含鉑雙藥化療聯合帕博利珠單抗組相比，蘆康沙妥珠單抗(sac-TMT)聯合治療組≥3級治療期間出現的不良事件(TEAE)發生率較低；導致劑量降低或永久停藥的TEAE發生率也較低。兩組間質性肺病/肺炎發生率相似。

同濟大學附屬東方醫院周彩存教授表示：「隨著OptiTROP-Lung06研究結果的讀出，我們進一步看到了蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗方案在PD-L1陰性、EGFR/ALK陰性晚期非鱗狀NSCLC一線治療中的臨床價值。結合此前2026年ASCO大會公佈的OptiTROP-Lung05研究成果，該聯合方案在不同PD-L1表達狀態的無驅動基因NSCLC患者中均顯示出PFS獲益，為其一線治療提供了新的III期研究證據。」

OptiTROP-Lung06研究

OptiTROP-Lung06(NCT06711900)是一項隨機、多中心、開放標籤III期研究，共納入455例患者，按1:1比例隨機接受蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗或含鉑雙藥化療(培美曲塞聯合順鉑或卡鉑)聯合帕博利珠單抗治療。主要終點為BICR評估的PFS，次要終點包括OS等。截至數據截止日期(2026年6月9日)，中位隨訪時間為9.7個月。這是全球首個ADC聯合免疫檢查點抑制劑在一線治療驅動基因陰性、PD-L1陰性非鱗狀NSCLC上達到主要終點的III期臨床研究。

關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊^®)

作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型TROP2 ADC，針對NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤及泌尿生殖系統腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)採用獨特雙功能連接子開發而成。該連接子一方面通過與抗TROP2單克隆抗體沙妥珠單抗形成不可逆結合，另一方面在溶酶體中可從貝洛替康衍生物拓撲異構酶I抑制劑有效載荷(KL610023)pH敏感裂解，從而最大限度將有效載荷遞送至腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。

於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。

截至目前，蘆康沙妥珠單抗(sac-TMT)的4項適應症已於中國獲批上市，分別用於：1)既往至少接受過2種系統治療(其中至少1種治療針對晚期或轉移性階段)的不可切除的局部晚期或轉移性三陰性乳腺癌(TNBC)；2)EGFR-酪氨酸激酶抑制劑(TKI)和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰性(HER2-) (免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲NMPA授予6項突破性療法認定。

蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。蘆康沙妥珠單抗(sac-TMT)的兩項新增適應症上市申請已獲NMPA受理，分別用於：1)聯合帕博利珠單抗一線治療PD-L1 TPS≥1%的EGFR基因突變陰性和ALK陰性的局部晚期或轉移性NSCLC；2)PD-L1綜合陽性評分(CPS)<10或早期階段接受過PD-1/PD-L1抑制劑的復發或轉移性TNBC的一線治療，以上兩項申請均被納入優先審評審批程序。目前，公司已在中國開展9項註冊性臨床研究。默沙東已啟動18項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平台，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30餘個重點創新藥項目，其中4個項目8個適應症已獲批上市，2個項目3個適應症處於NDA階段，10餘個項目正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平台OptiDC^TM，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。更多信息請訪問官網https://kelun-biotech.com/。

HONG KONG and SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- The Seminar on International Communication of Chinese and Foreign Enterprises' Green Development and Global Contributions was held at the Ping An Finance Center in Shenzhen on October 23. Hosted by the China Public Relations Association and co-organized by Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or the "Group"; HKEX: 2318; SSE: 601318), the seminar focused on APEC 2026's three priorities of openness, innovation and cooperation, with discussions also addressing green and sustainable development.

Participants exchanged practical experience in green development and global contributions by Chinese and international companies. The seminar aimed to build consensus, promote practical cooperation and further advance green development and mutual learning among civilizations in the lead-up to APEC Economic Leaders' Week in Shenzhen in November 2026.

Speakers included Guo Weimin, President of the China Public Relations Association; Robert Lawrence Kuhn, Chairman of The Kuhn Foundation (USA); Sha Hailin, President of the Shanghai Public Relations Association; and representatives from the Guangdong and Shenzhen government information offices.

More than 100 representatives from state-owned and private Chinese enterprises, multinational companies, research institutions, universities and media organizations attended the seminar. They discussed new approaches to cooperation on global ecological conservation and green development.

Climate governance, ecological conservation, and the green and low-carbon transition have become shared global priorities. Ping An remains committed to green development and continues to advance efforts toward China's carbon peaking and carbon neutrality goals. The Group integrates green development into its corporate strategy, business operations, technological innovation and external partnerships. It also actively participates in ecological restoration and biodiversity conservation and promotes the exchange of green technologies and experience across the Asia-Pacific region.

Empowering Green Development Through Finance and Advancing Biodiversity Conservation

At the seminar, Sheng Ruisheng, Board Secretary and Brand Director of Ping An Group, delivered a presentation titled "Living in Harmony with Nature: Ping An's Approach to Biodiversity Conservation." He shared Ping An's efforts to integrate green development principles into financial services, ecological conservation and public participation.

Sheng said Ping An remains committed to sustainable development and fully leverages its integrated financial capabilities to connect risk protection, public welfare initiatives and industrial development. Through a range of innovative measures covering urban environments, wetlands, rural areas, and ancient and notable trees, the Group is deeply engaged in biodiversity conservation.

Making buildings more migratory bird-friendly. Shenzhen lies along an important migratory bird route, where reflective glass façades can increase the risk of bird collisions. Ping An installed white dot-patterned anti-collision decals on Ping An Finance Center to make the glass more visible to birds and help reduce the risk of collisions.

Protecting wetland ecosystems. In 2023, Ping An established China's first charitable trust dedicated to mangrove ecological conservation. In March 2026, Ping An contributed an additional RMB950,190 to launch a demonstration project in Shenzhen Bay focused on key species protection, ecological conservation and nature education. The Group also launched a public welfare initiative to protect migratory bird habitats, inviting customers to participate in wetland conservation.

Balancing ecological conservation with industrial development. To support both conservation and local economic development, Ping An has introduced flower price index insurance and full-cost coffee insurance designed to help stabilize farmers' incomes, alongside credit, technology, production and sales support. The Group also provides public welfare insurance for wild mushroom poisoning, with RMB50 million in annual coverage. The program has provided assistance on 378 occasions to date.

In Gaoyou, Jiangsu Province, Ping An worked with the local forestry authorities to launch China's first rescue insurance policy for Oriental storks, successfully implementing an "insurance + rescue" funding model.

Protecting ancient and notable trees. Ping An provides risk protection for 80,000 ancient trees across China, with total coverage reaching RMB1.26 billion. In addition to insurance coverage, the Group has launched innovative public welfare programs combining ancient-tree conservation with specialty cultural tourism and youth health initiatives, helping preserve these centuries-old elements of China's natural heritage.

Taking Ping An's ecological conservation solutions global. Ping An is exploring full-cycle risk protection for Laos' rubber industry to support local ecological restoration and industrial development. The initial pilot is planned to cover approximately 1,200 hectares (18,000 mu), with estimated insurance coverage exceeding RMB54 million.

Ping An Unveils New Biodiversity Conservation Plan and Establishes Dedicated Egret Rescue Fund

During the seminar, participating institutions and companies presented the Joint Initiative on Ecological Conservation and Green Development by Chinese and Foreign Enterprises. The initiative sets out five priorities: putting ecology first, empowering development through innovation, promoting open collaboration, strengthening green communications, and encouraging multi-stakeholder participation. It calls on Chinese and international companies to work together to safeguard the coexistence of all living things and contribute to building an Asia-Pacific community.

As part of the initiative, Ping An announced a new biodiversity conservation plan aimed at protecting more rare and endangered species.

Chen Yao, General Manager of Ping An Group's Brand Communications Department, introduced two major initiatives under the plan.

First, Ping An will launch a dedicated conservation initiative for the Przewalski's gazelle, a species endemic to China. Found only around Qinghai Lake, the species faces significant conservation challenges and is listed as a Class 1 nationally protected wild animal in China.

The Group continues to work closely with conservation authorities across China. Through its agricultural drone program, Ping An Property & Casualty is providing drones to support wildlife population monitoring and habitat patrols across a 161-square-kilometer protected area, helping conservation teams identify injured wildlife and habitat disturbances while reducing frontline workloads.

Second, the Group is launching a comprehensive egret rescue program. Ping An has established a dedicated rescue fund for the Egret Garden at Sinopec Zhenhai Refining & Chemical Company. The fund will support professional organizations in rescuing eggs and chicks that require human intervention, treating injured or sick egrets, and providing care for injured migratory birds identified through the site's scientific monitoring program.

Ping An said biodiversity conservation is an important aspect of green development and concerns every individual, every family and every company. By fully leveraging its distinctive "insurance + technology" capabilities, the Group is helping protect the planet's rich diversity of life.

Looking ahead, Ping An hopes to work with stakeholders across society to advance biodiversity conservation and realize the shared vision of harmonious coexistence between people and nature.

About Ping An Insurance (Group) Company of China, Ltd.

Ping An Insurance (Group) Company of China, Ltd. (HKEX:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services. Under the technology-enabled "integrated finance + health and senior care" dual-pronged strategy, the Group provides professional "financial advisory, family doctor, and senior care concierge" services to its over 250 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses' quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of June 2026, Ping An had more than RMB14 trillion in total assets. The Group ranked 26th in the Forbes Global 2000 list in 2026, 48th in the Fortune Global 500 list in 2026, and ranked AAA in MSCI ESG Ratings in 2026.

For more information, please visit the www.group.pingan.com and follow our LinkedIn page - PING AN.

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, presented for the Phase 2 clinical data of its potential best-in-class IBI354 (HER2 ADC) as first-line treatment for breast cancer (BC) at the 2026 European Society for Medical Oncology (ESMO) Congress.

IBI354 has demonstrated encouraging antitumor activity and a highly favorable safety profile across multiple solid tumors. Two pivotal Phase 3 clinical studies (HeriCare-Ovarian01 and HeriCare-Breast01) have been initiated, which are expected to bring a next-generation ADC treatment option with high efficacy and low toxicity to ovarian cancer, breast cancer, and other tumor types. IBI354 also validates the differentiated advantages of Innovent's ADC technology platform and lay the foundation for the development of its next-generation bispecific ADCs and dual-payload ADCs.

1776P - IBI354 plus pertuzumab as first-line (1L) treatment for patients (pts) with HER2-positive, unresectable locally advanced or metastatic breast cancer (BC): Results from a phase 2 study 

This study was designed to evaluate the efficacy and safety of IBI354 in combination with pertuzumab in patients with HER2-positive, unresectable locally advanced, or metastatic breast cancer. As of July 1, a total of 20 patients were enrolled to receive IBI354 9mg/kg Q3W in combination with pertuzumab, with a median follow-up of 9.6 months (range: 9–11) and a median treatment duration of 42.21 weeks (range: 24.1–49.0).

IBI354 in combination with pertuzumab demonstrated encouraging efficacy signals.
In patients receiving first-line treatment for HER2-positive breast cancer, the confirmed objective response rate (cORR) and disease control rate (DCR) were 95% and 100%, respectively. The median follow-up for progression-free survival (PFS) was 8.3 months. Both PFS and OS were not yet mature, with only 1 PFS event and no OS events.

IBI354 in combination with pertuzumab demonstrated a favorable safety profile.
The most common treatment-emergent adverse events (TEAEs) were nausea, vomiting, and anemia. No interstitial lung disease (ILD) occurred. Overall, 4 patients (20%) experienced Grade ≥3 treatment-related adverse events (TRAEs), 2 patients (10%) had dose interruptions due to TRAEs, no patients had dose reductions due to TRAEs, 1 patient (5%) discontinued treatment due to a TRAE, and no TRAE led to death.

Professor Xiaohua Zeng of Chongqing University Cancer Hospital stated: "HER2-positive advanced breast cancer is an important research direction in the field of precision treatment for breast cancer. In recent years, with the continuous development of anti-HER2 therapies and ADC drugs, patients have increasingly rich treatment options, and clinical outcomes have been significantly improved. At the same time, however, we should recognize that the treatment of advanced breast cancer is a long-term management endeavor. How to further optimize safety and improve patient tolerance while ensuring antitumor efficacy remains a topic requiring continued exploration in clinical practice. IBI354 has shown a very favorable safety profile, with no severe interstitial lung disease or ocular toxicity commonly observed with other ADC drugs, and a cORR of 95%. I look forward to further research results that will validate the long-term benefits for patients treated with IBI354."

Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent Biologics, stated: "As ADCs continue to advance cancer treatment, we are expanding our ADC pipeline and strengthening our capabilities. The latest breast cancer data for IBI354 presented at this year's ESMO Congress add to the growing body of clinical evidence supporting its ongoing development. We have initiated a Phase 3 study evaluating IBI354 as a first-line treatment for HER2-positive advanced breast cancer, with additional Phase 3 studies being planned. Guided by unmet patient needs, we remain committed to advancing next-generation ADCs with the goal of delivering meaningful improvements in cancer care."

About IBI354

IBI354 is an innovative HER2-targeted antibody–drug conjugate developed using Innovent's proprietary SoloTx^® ADC platform. Based on this platform, Innovent is promoting clinical trial studies multiple self-developed ADC molecules, which have shown promising safety and efficacy signals.

With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors.

Starting from the urgent clinical needs, in addition to the Phase 3 studies (HeriCare-Breast01 and HeriCare-Ovarian01) already initiated in BC and PROC, Innovent will explore IBI354 in multiple solid tumor indications including adjuvant therapy and neoadjuvant therapy for BC.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage.

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China's innovative drug industry.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.